POSTER SESSION II Monday, March 24, 2003   —  1:00 - 4:30 PM Exhibit Hall A - C HEMATOPATHOLOGY 128 Feasibility of the WHO Classification for Malignant Lymphoma under a Limited Source of Information (1159) S Sukpanichnant Siriraj Hospital, Mahidol University, Bangkok, Thailand 129 Non Hodgkin Lymphomas in Argentina According to the World Health Organization Classification of Lymphoid Neoplasms. Incidence of Entities. A Retrospective Study of 360 Cases (1172) A Vijnovich-Baron, N Tartas, J Sanchez-Avalos, L Barazzutti, J Korin, H Ferro, I Santos, A Musso, M Alcon-Alvarez, G Lucero Argentina; Hospital Militar, Argentina; Bs As., Argentina 130 A Histopathologic Study of Hematolymphoid Specimens from Persian Gulf War Military Veterans (1100) ER Ladich, MR Lewin-Smith, CS Specht, SL Abbondanzo, AL Moroz, VF Kalasinsky, FG Mullick Armed Forces Institute of Pathology, Washington, DC 131 B and T Cell Clonality Testing - A Comparison of Two Assays (1075) RP Hermann, VR Mas, CT Garrett, S Nasim, A Ferreira-Gonzalez Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, VA 132 Simian Virus 40 Sequences Are Present at High Frequency, but Low Copy Number in Both Lymphomas and Benign Tissues (1062) K Fu, D Scanlan, P Aoun, J Chan, D Weisenburger, T Greiner University of Nebraska Medical Center, Omaha, NE 133 C-Myc Rearrangement in Typical Burkitt and Atypical Burkitt Lymphoma (1179) DD Weisenburger, K Fu, DJ Pickering, P Aoun, TC Greiner, WC Chan, WG Sanger University of Nebraska Medical Center, Omaha, NE 134 CD56 and CD10-Positive B-Cell Lymphoma (1178) J Weisberger, W Gorczyca, Z Liu, M Goldstein, S Tugulea IMPATH, Inc., New York City, NY 135 Differential Expression of WT-1 Gene Product in Non-Hodgkin's Lymphomas (NHL) (1054) E Drakos, GZ Rassidakis, P Tsioli, Y Ma, R Lai, D Jones, LJ Medeiros University of Texas MD Anderson Cancer Center, Houston, TX 136 Activation Status of MAPK and Akt in B Cell Lymphomas (1102) E Levi, G Bentley, J Frank, R VanderHeide John D. Dingell VA Medical Center, Detroit, MI; Harper Hospital, Wayne State University, Detroit, MI 137 The Expresson Patterns of BCL-6 and eIF 4E in Non-Hodgkin Lymphomas (1181) J Wu, MR Fowler Louisiana State University Health Sciences Center, Shreveport, LA 138 PAX5 Expressions in Hematologic Malignancies (1192) X Zhang, Z Lin, I Kim Korea University Medical College, Seoul, Korea 139 BCL-2 mRNA Expression Is Proportional to Its Protein Level in Normal and Malignant B Cells (1151) Y Shen, G Zhou, RS Wickert, JC Chan University of Nebraska Medical Center, Omaha, NE 140 Loss of Major Histocompatibility Complex (MHC) Class II Gene Expression Predicts Poor Survival in Diffuse Large B Cell Lymphoma (DLBCL) (1141) LM Rimsza, M LeBlanc, R Braziel, M Jaramillo, TP Miller, L Staudt, TM Grogan, R Fisher University of Arizona, Tucson, AZ; Southwest Oncology Group, Seattle, WA; Oregon Health Sciences Center, Portland, OR; National Institute of Health, Bethesda, MD; University of Rochester, Rochester, NY 141 Expression of Pan B Cell Antigens in Diffuse Large B Cell Lymphoma: Potential Implications for Prognosis and Immunotherapy (1165) E Torlakovic, J Linderoth, M Jerkeman, S Kvaloy The Norwegian Radium Hospital, Oslo, Norway; Lund University Hospital, Lund, Sweden 142 Intratumoral T Cells and Aberrant Expression of T Cell Antigens in Diffuse Large B Cell Lymphoma (1164) E Torlakovic, J Linderoth, M Jerkeman, S Kvaloy The Norwegian Radium Hospital, Oslo, Norway; Lund University Hospital, Lund, Sweden 143 "Grey Zone" Lymphomas: A Histologic, Immunophenotypic and Molecular Study of 10 Cases of CD20+ CD30+ Large B-Cell Neoplasms (1042) A Chiu, E Hyjek, JW Lee, MD Kraus, SA Ely, A Chadburn, G Frizzera Weill Medical College of Cornell University, New York, NY 144 Tissue Microarray (TMA) Analysis of Survivin Expression in Benign Lymphoid Tissue and Small B-Cell Non-Hodgkin Lymphoma (NHL) (1170) R Valdez, B Schnitzer, WG Finn University of Michigan, Ann Arbor, MI 145 Clinical Outcome and Immunophenotypic Changes in B-Cell Lymphoma Treated with Rituximab (1148) RM Seliem, JK Freeman, RH Steingart, G Chow, RP Hasserjian Baystate Medical Center, Western Campus of Tufts University, Springfield, MA 146 JAK/STAT3 Signaling Pathway in Mantle Cell Lymphoma (MCL) (1188) MA Yared, LJ Medeiros, JD Khoury, GZ Rassidakis, V Leventaki, R Lai University of Texas M.D. Anderson Cancer Center, Houston, TX 147 Correlation of SOCS3 Expression with STAT3 Activation in Mantle Cell Lymphoma (MCL) (1187) MA Yared, LJ Medeiros, JD Khoury, GZ Rassidakis, V Leventaki, R Lai University of Texas M.D. Anderson Cancer Center, Houston, TX 148 Molecular Heterogeneity in Mantle Cell Lymphoma (1037) FI Camacho, P Algara, N Martinez, M Mollejo, E Campo, JA Martinez-Climent, F Sole, M Gonzalez, J Menarguez, JF Garcia Centro Nacional de Investigaciones Oncologicas, Madrid; Hospital Virgen de la Salud, Toledo; Hospital Clinico y Provincial, Barcelona; Hospital Clinico Universitario, Valencia; Hospital del Mar, Barcelona; Hospital Clinico, Salamanca; Hospital Gregorio Maranon, Madrid, Spain 149 Morphologic Spectrum of Mantle Cell Lymphoma (MCL): Value of Proliferative Activity for Diagnosis and Subclassification (1119) KA Monnin, R Lai, DS Viswanatha, K Foucar, LJ Medeiros, CS Wilson University of New Mexico Health Sciences Center, Albuquerque, NM; University of Texas M.D. Anderson Cancer Center, Houston, TX 150 HLA-DO Is a Useful Marker To Distinguish Florid Follicular Hyperplasia from Follicular Lymphoma by Flow Cytometry (1104) S Li, X Chen, PE Jensen Emory University School of Medicine, Atlanta, GA 151 Transformation of Follicular Lymphoma: A Comparative Genomic Hybridization Study (1050) A Director-Myska, SL Abbondanzo, TJ O'Leary Armed Forces Institute of Pathology, Rockville, MD; Armed Forces Institute of Pathology, Washington, DC